康柏西普联合曲安奈德球内注射治疗糖尿病黄斑水肿

Intravitreal injection of conbercept combined with triamcinolone acetonide for diabetic macular edema

目的:探讨康柏西普联合曲安奈德球内注射治疗糖尿病性黄斑水肿的疗效。方法:回顾性队列研究。合并黄斑水肿的糖尿病患者40例43眼,治疗前记录BCVA、IOP和OCT检查。根据治疗方式分为两组,A组患者给予玻璃体腔注射康柏西普联合曲安奈德治疗,B组给予玻璃体腔注射康柏西普治疗。分别于治疗后1d,1、4、8、12、24wk记录BCVA、IOP和CMT及并发症等情况。结果:A组治疗后不同时间点的视力与治疗前(0.83±0.03)相比均有差异(P<0.05),治疗8wk时达到最佳视力(0.23±0.04);治疗后CMT与治疗前(612.4±47.6μm)有差异(P<0.05);24wk内平均注射次数2.7次。B组治疗后不同时间点视力与治疗前(0.79±0.09)有差异(P<0.05),治疗4wk时达到最佳视力(0.25±0.06)。治疗后CMT与治疗前(597.8±62.4μm)有差异(P<0.05),24wk内平均注射次数3.6次。两组患者第一针与第二针治疗间隔时间有差异(P<0.05)。两组患者治疗前后眼压无差异(P>0.05)。结论:康柏西普联合曲安奈德球内注射治疗糖尿病性黄斑水肿安全、有效、见效快,但疗效更持久,且可降低打针频率。

·AIM:To investigate the therapeutic effects of intravitreal injection of conbercept combined with triamcinolone acetonide for diabetic macular edema(DME).·METHODS:This retrospective cohort study comprised of 43 eyes in 40 patients who suffered from DME.There were 2 groups,groups A and B,according to the different therapies.Group A(22 eyes of 21 patients)were treated with intravitreal injection of 0.5 mg/0.05 mL conbercept and 2 mg triamcinolone acetonide(TA).Group B(21 eyes of 19 patients)were treated with intravitreal injection of 0.5 mg/0.05 mL conbercept.All the patients were followed up to 24 wk.The best corrected visual acuity(BCVA),intraocular pressure(IOP),central macular thickness(CMT)and complications were recorded and analyzed prior to operation and 1 d,1 wk,4 wk,8 wk,12 wk and 24 wk after operation.·RESULTS:Group A:the BCVA of 22 eyes of 21 patients treated with intravitreal injection of 0.5 mg/0.05 mL and 2 mg triamcinolone acetonide on 1 d,1 wk,4 wk,8 wk,12 wk and 24 wk were significantly different from that(LogMAR 0.83±0.03)prior to treatment(P<0.05),and the BCVA was achieved at 8 wk(LogMAR 0.23±0.04).The CMT were significantly different from that(612.4±47.6μm)prior to treatment(P<0.05).The average number of injections was 2.7 injections within 24 wk;Group B:the VA of 21 eyes in 21 patients treated with intravitreal injection of 0.5 mg/0.05 mL on 1 d,1 wk,4 wk,8 wk,12 wk and 24 wk were significantly different from that(LogMAR 0.79±0.09)prior to treatment(P<0.05),and the BCVA was achieved at 4 wk(LogMAR 0.25±0.06).The CMT were significantly different from that(597.8±62.4μm)prior to treatment(P<0.05).The average number of injections was 3.6 injections within 24 wk.There was statistically significant difference in the interval between the first and second injections of two groups(P<0.05).There were no significant difference in IOP.·CONCLUSION:In summary,combined intravitreal injection of conbercept and TA is a safe and effective treatment for DME.The effect is more durable and the injection frequency can be reduced.The combination of anti-VEGF and corticosteroids may be an effective treatment for DME.